Insider Buying: Burning Rock Biotech (NASDAQ:BNR) Director Buys $779,642.50 in Stock

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han acquired 104,650 shares of Burning Rock Biotech stock in a transaction dated Monday, June 22nd. The stock was purchased at an average cost of $7.45 per share, with a total value of $779,642.50. Following the completion of the purchase, the director owned 18,123,196 shares of the company’s stock, valued at approximately $135,017,810.20. This represents a 0.58% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Yusheng Han also recently made the following trade(s):

• On Friday, June 26th, Yusheng Han bought 24,900 shares of Burning Rock Biotech stock. The shares were purchased at an average price of $8.00 per share, for a total transaction of $199,200.00.
• On Wednesday, June 24th, Yusheng Han bought 250,000 shares of Burning Rock Biotech stock. The shares were purchased at an average price of $8.00 per share, for a total transaction of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han bought 5,990 shares of Burning Rock Biotech stock. The stock was purchased at an average cost of $7.50 per share, with a total value of $44,925.00.
• On Tuesday, June 16th, Yusheng Han purchased 111,110 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $9.00 per share, with a total value of $999,990.00.
• On Friday, June 12th, Yusheng Han purchased 210,000 shares of Burning Rock Biotech stock. The stock was acquired at an average price of $9.25 per share, with a total value of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han purchased 24,760 shares of Burning Rock Biotech stock. The shares were acquired at an average cost of $8.74 per share, for a total transaction of $216,402.40.

Burning Rock Biotech Price Performance

Shares of Burning Rock Biotech stock opened at $9.82 on Friday. The stock’s 50-day simple moving average is $12.35 and its 200-day simple moving average is $19.96. Burning Rock Biotech Limited Sponsored ADR has a 52 week low of $3.23 and a 52 week high of $41.72. The company has a market capitalization of $103.31 million, a price-to-earnings ratio of -11.98 and a beta of 1.32. The company has a quick ratio of 2.81, a current ratio of 3.05 and a debt-to-equity ratio of 0.06.

Burning Rock Biotech (NASDAQ:BNR) last released its quarterly earnings data on Tuesday, June 9th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.29) by $2.09. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.The firm had revenue of $15.66 million during the quarter, compared to analyst estimates of $19.21 million.

Wall Street Analysts Forecast Growth

BNR has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a research note on Monday, April 20th. Wall Street Zen cut shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Burning Rock Biotech presently has an average rating of “Sell”.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in BNR. Crcm LP increased its holdings in shares of Burning Rock Biotech by 121.8% in the fourth quarter. Crcm LP now owns 491,426 shares of the company’s stock worth $9,902,000 after purchasing an additional 269,851 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Burning Rock Biotech in the fourth quarter worth about $220,000. Prospera Financial Services Inc boosted its stake in Burning Rock Biotech by 26.0% during the fourth quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after buying an additional 6,430 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Burning Rock Biotech by 13.8% during the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock valued at $571,000 after buying an additional 4,290 shares during the last quarter. Hedge funds and other institutional investors own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.